Optimum treatment of intracellular infection

被引:37
作者
Maurin, M [1 ]
Raoult, D [1 ]
机构
[1] FAC MED TIMONE, CNRS EP J0054, UNITE RICKETTSIES, F-13385 MARSEILLE 5, FRANCE
关键词
D O I
10.2165/00003495-199652010-00004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The intracellular location of some micro-organisms has been early recognised as a critical point to explain failure of antibiotic therapy to eradicate such pathogens from infected hosts, Most often parasites invade 'professional' phagocytic cells, including neutrophils, monocytes and macrophages, by resisting the intracellular bactericidal phagolysosomal pathway, Alternatively, they may invade 'nonprofessional' phagocytic cells (cells with fewer phagocytic and bactericidal abilities) such as endothelial cells, or even cells without lysosomes such as erythrocytes. The intracellular activity of an antibiotic depends on several factors including its ability to reach the eukaryotic cell membrane, its subcellular localisation as compared to that of the parasite, the possibility that the intracellular milieu may partially inactivate its activity, and the susceptibility of the intracellular form of the parasite. In vitro and animal models have been developed to investigate anti biotic activity against intracellular pathogens, However, it should be emphasised that only data obtained from patients give reliable information to define the optimum antibiotic regimen.
引用
收藏
页码:45 / 59
页数:15
相关论文
共 127 条
  • [1] COMPARISON OF 3 DIFFERENT REGIMENS IN THE TREATMENT OF ACUTE BRUCELLOSIS - A MULTICENTER MULTINATIONAL STUDY
    ACOCELLA, G
    BERTRAND, A
    BEYTOUT, J
    DURRANDE, JB
    RODRIGUEZ, JAG
    KOSMIDIS, J
    MICOUD, M
    REY, M
    ZAPATA, MR
    ROUX, J
    STAHL, JP
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1989, 23 (03) : 433 - 439
  • [2] AN INVITRO EVALUATION OF THE CELLULAR UPTAKE AND INTRAPHAGOCYTIC BIOACTIVITY OF CLARITHROMYCIN (A-56268, TE-031), A NEW MACROLIDE ANTIMICROBIAL AGENT
    ANDERSON, R
    JOONE, G
    VANRENSBURG, CEJ
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 22 (06) : 923 - 933
  • [3] PARASITOPHOROUS VACUOLES OF LEISHMANIA-AMAZONENSIS-INFECTED MACROPHAGES MAINTAIN AN ACIDIC PH
    ANTOINE, JC
    PRINA, E
    JOUANNE, C
    BONGRAND, P
    [J]. INFECTION AND IMMUNITY, 1990, 58 (03) : 779 - 787
  • [4] TREATMENT OF HUMAN BRUCELLOSIS WITH DOXYCYCLINE PLUS RIFAMPIN OR DOXYCYCLINE PLUS STREPTOMYCIN - A RANDOMIZED, DOUBLE-BLIND-STUDY
    ARIZA, J
    GUDIOL, F
    PALLARES, R
    VILADRICH, PF
    RUFI, G
    CORREDOIRA, J
    MIRAVITLLES, MR
    [J]. ANNALS OF INTERNAL MEDICINE, 1992, 117 (01) : 25 - 30
  • [5] ARNOLD K, 1993, AM J MED, V94, P195
  • [6] RANDOMIZED TRIAL OF 5-DAY RIFAMPIN VERSUS 1-DAY DOXYCYCLINE THERAPY FOR MEDITERRANEAN SPOTTED-FEVER
    BELLA, F
    ESPEJO, E
    URIZ, S
    SERRANO, JA
    ALEGRE, MD
    TORT, J
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1991, 164 (02) : 433 - 434
  • [7] BELLACUETO F, 1987, J INFECT DIS, V155, P1056, DOI 10.1093/infdis/155.5.1056
  • [8] BERNARD E, 1989, REV INFECT DIS, V11, pS989
  • [9] AIDS-ASSOCIATED MYCOPLASMAS
    BLANCHARD, A
    MONTAGNIER, L
    [J]. ANNUAL REVIEW OF MICROBIOLOGY, 1994, 48 : 687 - 712
  • [10] PROPOSAL OF AFIPIA GEN-NOV, WITH AFIPIA-FELIS SP-NOV (FORMERLY THE CAT SCRATCH DISEASE BACILLUS), AFIPIA-CLEVELANDENSIS SP-NOV (FORMERLY THE CLEVELAND-CLINIC-FOUNDATION STRAIN), AFIPIA-BROOMEAE SP-NOV, AND 3 UNNAMED GENOSPECIES
    BRENNER, DJ
    HOLLIS, DG
    MOSS, CW
    ENGLISH, CK
    HALL, GS
    VINCENT, J
    RADOSEVIC, J
    BIRKNESS, KA
    BIBB, WF
    QUINN, FD
    SWAMINATHAN, B
    WEAVER, RE
    REEVES, MW
    OCONNOR, SP
    HAYES, PS
    TENOVER, FC
    STEIGERWALT, AG
    PERKINS, BA
    DANESHVAR, MI
    HILL, BC
    WASHINGTON, JA
    WOODS, TC
    HUNTER, SB
    HADFIELD, TL
    AJELLO, GW
    KAUFMANN, AF
    WEAR, DJ
    WENGER, JD
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1991, 29 (11) : 2450 - 2460